 Idiopathic Pulmonary Fibrosis
"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Descriptor ID |
D054990
|
| MeSH Number(s) |
C08.381.483.487.500 C08.381.765.500
|
| Concept/Terms |
Idiopathic Pulmonary Fibrosis- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibroses
- Pulmonary Fibroses, Idiopathic
- Familial Idiopathic Pulmonary Fibrosis
- Fibrocystic Pulmonary Dysplasia
- Dysplasia, Fibrocystic Pulmonary
- Dysplasias, Fibrocystic Pulmonary
- Fibrocystic Pulmonary Dysplasias
- Pulmonary Dysplasia, Fibrocystic
- Pulmonary Dysplasias, Fibrocystic
- Fibrosing Alveolitis, Cryptogenic
- Hamman-Rich Disease
- Disease, Hamman-Rich
- Diseases, Hamman-Rich
- Hamman Rich Disease
- Hamman-Rich Diseases
- Interstitial Pneumonitis, Usual
- Interstitial Pneumonitides, Usual
- Pneumonitides, Usual Interstitial
- Pneumonitis, Usual Interstitial
- Usual Interstitial Pneumonitides
- Usual Interstitial Pneumonitis
- Pulmonary Fibrosis, Idiopathic
- Usual Interstitial Pneumonia
- Interstitial Pneumonia, Usual
- Interstitial Pneumonias, Usual
- Usual Interstitial Pneumonias
- Idiopathic Fibrosing Alveolitis, Chronic Form
- Cryptogenic Fibrosing Alveolitis
- Cryptogenic Fibrosing Alveolitides
- Fibrosing Alveolitides, Cryptogenic
- Idiopathic Pulmonary Fibrosis, Familial
|
Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".
This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 | | 2009 | 10 | 2 | 12 | | 2010 | 4 | 0 | 4 | | 2011 | 11 | 1 | 12 | | 2012 | 15 | 1 | 16 | | 2013 | 15 | 0 | 15 | | 2014 | 19 | 2 | 21 | | 2015 | 25 | 3 | 28 | | 2016 | 19 | 3 | 22 | | 2017 | 28 | 1 | 29 | | 2018 | 23 | 2 | 25 | | 2019 | 23 | 1 | 24 | | 2020 | 15 | 1 | 16 | | 2021 | 22 | 0 | 22 | | 2022 | 36 | 0 | 36 | | 2023 | 31 | 0 | 31 | | 2024 | 22 | 4 | 26 | | 2025 | 16 | 3 | 19 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
Redente EF, Song T, Javkhlan N, Edelman BL, Foster DG, Wilson JA, Chakraborty S, Cooley JC, Gaurav R, Saguthi S, Seibold MA, Blumhagen RZ, Schwartz DA, Yang IV, Matsuda J, Bridges JP, Zemans RL, Tuder RM, Riches DWH. Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition. Nat Commun. 2026 Feb 28; 17(1).
-
Mackintosh JA, Walsh SLF, Silva M, Calandriello L, Humphries SM, Lynch DA, Jo HE, Glaspole I, Grainge C, Goh N, Hopkins PMA, Moodley Y, Reynolds PN, Zappala C, Keir G, Cooper WA, Mahar AM, Ellis S, Wells AU, Corte TJ. Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis. Respirology. 2026 May; 31(5):521-529.
-
Kim SH, Nouws J, Ruwisch J, Woodard GA, Cooley J, Khoury J, Sun H, Doherty E, Piecychna M, Manning EP, Kang MJ, Bruscia EM, Wei H, Zhang Y, Yarovinsky TO, Hwa J, Zacharias WJ, Ingram J, Lee CG, Elias JA, Kaminski N, Redente EF, Herzog EL, Prasse A, Bucala R, Sauler M. Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor-CD74 signaling. Sci Transl Med. 2025 Dec 03; 17(827):eadr2277.
-
Kim JS, Pugashetti J, Ma SF, Huang Y, Podolanczuk AJ, Lynch DA, Oh A, Mychaleckyj J, Manichaikul A, Rich S, Chua F, Adams TM, Flaherty KR, Lee JS, Lasky JA, Raghu G, Murray S, Spino C, Martinez FJ, Noth I, Humphries SM, Adegunsoye A, Molyneaux PL, Oldham JM, Newton CA. Associations of interstitial lung disease subtype and CT pattern with lung function and survival. Thorax. 2025 Nov 14; 80(12):927-934.
-
Guiot J, Engelberts J, Henket M, Ernst B, Maloir Q, Louis R, Lynch DA, Humphries SM, Charbonnier JP. Fibrotic and vascular abnormalities quantified by an AI-based model are associated with outcomes in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2025 Oct 24; 25(1):488.
-
Bousamaki J, Rørbeck EA, Petersen AG, Korntner SH, Pors SE, Redente EF, Oró D, Salinas CG, Olsen RW, Simonsen U, Feigh M, Hansen HH. Distinct lung functional, histological and cell senescence signatures in the single and repetitive bleomycin mouse models of idiopathic pulmonary fibrosis. Physiol Rep. 2025 Sep; 13(18):e70560.
-
Fortier SM, Redente EF, Peters-Golden M. Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution. Semin Respir Crit Care Med. 2025 Aug; 46(4):298-310.
-
Brazee P, Allen N, Knipe R, Redente EF, Le Saux CJ. Peeling Back the Layers of the Bleomycin Model of Lung Fibrosis: Lessons Learned, Factors to Consider, and Future Directions. Semin Respir Crit Care Med. 2025 Aug; 46(4):330-346.
-
Tanneberger AE, Blomberg R, Kary AD, Lu A, Riches DWH, Magin CM. Biomaterial-based 3D human lung models replicate pathological characteristics of early pulmonary fibrosis. Acta Biomater. 2025 Sep 15; 204:277-292.
-
Wagner DE, Alsafadi HN, Mitash N, Justet A, Hu Q, Pineda R, Staab-Weijnitz C, Korfei M, Gvazava N, Wannemo K, Onwuka U, Mozurak M, Estrada-Bernal A, Cala-Garcia J, Mutze K, Costa R, Bölükbas D, Stegmayr J, Skronska-Wasek W, Klee S, Ota C, Baarsma HA, Wang J, Sembrat J, Hilgendorff A, Ding J, Günther A, Chambers R, Rosas I, de Langhe S, Kaminski N, Lehmann M, Eickelberg O, Königshoff M. Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models. Nat Commun. 2025 Aug 02; 16(1):7099.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|